From the Guidelines
Adults aged 60 years and older should receive a single dose of RSV vaccine, with no booster dose recommended at this time, as a single dose provides protection for at least two RSV seasons 1. The current recommendations from the Advisory Committee on Immunization Practices (ACIP) suggest that eligible adults, including those aged 75 years and older, as well as those aged 60-74 years with increased risk for severe RSV disease, should receive a single dose of RSV vaccine 1. Key points to consider include:
- Adults who have previously received RSV vaccine should not receive another dose 1
- Eligible adults can be vaccinated at any time of year, but vaccination will have the most benefit if administered in late summer or early fall, just before the RSV season 1
- The need for additional RSV vaccine doses will be evaluated by ACIP in the future, and recommendations will be updated as needed 1 It is essential for adults aged 60 years and older to consult with their healthcare provider to determine if RSV vaccination is appropriate for them, considering individual risk factors 1.
From the Research
Recommended Frequency for Receiving RSV Booster Vaccinations as an Adult
- The recommended frequency for receiving Respiratory Syncytial Virus (RSV) booster vaccinations as an adult is not explicitly stated in the provided studies 2, 3, 4, 5, 6.
- However, it is mentioned that RSV vaccines have demonstrated moderate to high efficacy in preventing RSV-associated lower respiratory tract disease and have the potential to prevent substantial morbidity and mortality among older adults 4.
- The Advisory Committee on Immunization Practices (ACIP) recommends that adults aged ≥60 years may receive a single dose of an RSV vaccine, using shared clinical decision-making 4.
- There is no mention of a booster vaccination schedule, but it is noted that postmarketing surveillance will direct future guidance 4.
- The studies suggest that RSV vaccine efficacy decreases over time, which should be anticipated for a virus that is characterized by short-term immunity 5.
- Ongoing vaccine surveillance and further evaluation, particularly among immunocompromised patients, frail elderly subjects, and young infants, are necessary to determine the optimal vaccination schedule 5.